SYRE vs BMRN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BMRN Captures Institutional Edge (2โ2 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioMarin Pharmaceuticals Inc (BMRN) driven by superior Valuation, Growth & Margin while SYRE counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, SYRE trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus BMRN at 9.1x Forward P/E and 16.3% operating margin (+32.0% YoY). In options structure, SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro) against BMRN sits in CONSOLIDATION (17th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SYRE | BMRN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $9.8B | $11.0B | Larger Scale | BMRN |
| Trailing P/E Ratio Valuation | N/M | 8.8x | Lower Multiple | BMRN |
| Forward P/E Ratio Valuation | N/M | 9.1x | Lower Multiple | BMRN |
| Revenue Growth (YoY) Growth | +0.0% | +32.0% | Higher Growth | BMRN |
| Operating Margin (TTM) Profitability | 0.0% | 16.3% | Higher Margin | BMRN |
| Net Profit Margin Profitability | 0.0% | -0.5% | Higher Margin | SYRE |
| Return on Equity (ROE) Capital Efficiency | -35.0% | -0.3% | Higher ROE | BMRN |
| 52-Week Range Position Momentum | 88% ($22โ$111) | 42% ($49โ$71) | Stronger Trend | SYRE |
| Beta / 30D Volatility Risk Regime | 1.75ฮฒ ยท 59% Vol | 0.28ฮฒ ยท 31% Vol | Lower Realized Risk | BMRN |
| Unified Institutional Score Composite Signal | 36.1 / 100 (SELL) | 52.3 / 100 (HOLD) | Higher Composite | BMRN |